Startseite>>Signaling Pathways>> Immunology/Inflammation>> Reactive Oxygen Species>>Efaproxiral (RSR13)

Efaproxiral (RSR13) (Synonyms: RSR 13)

Katalog-Nr.GC32887

Efaproxiral (RSR13) ist ein synthetischer allosterischer Modifikator von HÄmoglobin (Hb), der die Hb-Sauerstoff (O2)-BindungsaffinitÄt verringert und die Oxygenierung von hypoxischen Tumoren wÄhrend der Strahlentherapie verbessert.

Products are for research use only. Not for human use. We do not sell to patients.

Efaproxiral (RSR13) Chemische Struktur

Cas No.: 131179-95-8

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
71,00 $
Auf Lager
50mg
65,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Efaproxiral is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy.in vitro: Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. Efaproxiral can enhance the oxygenation of hypoxic tumours and function as a radiation sensitiser, increasing the effectiveness of RT.

[1]. Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94(12):1777-1784.

Bewertungen

Review for Efaproxiral (RSR13)

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Efaproxiral (RSR13)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.